Special Masters Back Atty Fee Bid In $688M Vytorin Deal
By Linda Chiem ( August 29, 2013, 3:04 PM EDT) -- Two special masters recommended Wednesday that a New Jersey federal court approve $140 million in attorneys' fees sought by class counsel who settled for $688 million two securities class actions alleging Merck & Co. and its Schering-Plough subsidiary hid test results on the efficacy of their anti-cholesterol drug Vytorin....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.